Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Research output: Contribution to journalArticle

Abstract

To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers.

Details

Authors
  • Kelly-Anne Phillips
  • Roger L Milne
  • Matti A Rookus
  • Mary B Daly
  • Antonis C Antoniou
  • Susan Peock
  • Debra Frost
  • Douglas F Easton
  • Steve Ellis
  • Michael L Friedlander
  • Saundra S Buys
  • Nadine Andrieu
  • Catherine Noguès
  • Dominique Stoppa-Lyonnet
  • Valérie Bonadona
  • Pascal Pujol
  • Sue Anne McLachlan
  • Esther M John
  • Maartje J Hooning
  • Caroline Seynaeve
  • Rob A E M Tollenaar
  • David E Goldgar
  • Mary Beth Terry
  • Trinidad Caldes
  • Prue C Weideman
  • Irene L Andrulis
  • Christian F Singer
  • Kate Birch
  • Jacques Simard
  • Melissa C Southey
  • Anna Jakubowska
  • Edith Olah
  • Anne-Marie Gerdes
  • Lenka Foretova
  • John L Hopper
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)3091
JournalJournal of Clinical Oncology
Volume31
Issue number25
Publication statusPublished - 2013
Publication categoryResearch
Peer-reviewedYes